To access the full text documents, please follow this link: http://hdl.handle.net/2445/148127
dc.contributor.author | Pacchiarotti, Isabella |
---|---|
dc.contributor.author | Tiihonen, Jari |
dc.contributor.author | Kotzalidis, Georgios D. |
dc.contributor.author | Verdolini, Norma |
dc.contributor.author | Murru, Andrea |
dc.contributor.author | Goikolea, José Manuel |
dc.contributor.author | Valentí Ribas, Marc |
dc.contributor.author | Aedo, Alberto |
dc.contributor.author | Vieta i Pascual, Eduard, 1963- |
dc.date | 2020-01-17T15:35:25Z |
dc.date | 2020-02-12T06:10:20Z |
dc.date | 2019-04 |
dc.date | 2020-01-17T15:35:26Z |
dc.identifier | 0924-977X |
dc.identifier | http://hdl.handle.net/2445/148127 |
dc.identifier | 685977 |
dc.identifier | 4207789 |
dc.identifier.uri | http://hdl.handle.net/2445/148127 |
dc.description | Long-Acting Injectable Antipsychotics (LAIs) are used to overcome non-compliance in psychoses, mainly schizophrenia spectrum disorders. We aimed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder (BD) and/or Schizoaffective Disorder (SAD). We searched six databases from inception to 28-March-2018, using the strategy: long-acting antipsychotics AND (bipolar disorder OR schizoaffective disorder OR mania OR manic OR bipolar depression). We included peer-reviewed double-blind comparisons of LAIs for any clinical outcome occurrence in BD, or open mirror studies with same prospective as retrospective assessment periods. We excluded studies reporting on mixed schizophrenia/SAD populations without reporting results separately. The pooled records amounted to 642. After duplicate removal and inclusion/exclusion criteria application, we included 15 studies, 6 double-blind and 9 open, 13 assessing BD and 2 SAD. Depot neuroleptics prevented manic, but not depressive recurrences and may worsen depressive symptoms. Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo, but not from depressive recurrences. Add-on or monotherapy paliperidone palmitate in SAD patients protected from psychotic, depressive, and manic symptoms. In patients with BD-I with a manic episode at study enrolment, aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes. LAIs are effective and well-tolerated maintenance treatments for BD and SAD. They showed better efficacy in preventing mania than depression. LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems. |
dc.format | 14 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Elsevier B.V. |
dc.relation | Versió postprint del document publicat a: https://doi.org/10.1016/j.euroneuro.2019.02.003 |
dc.relation | European Neuropsychopharmacology, 2019, vol. 29, num. 4, p. 457-470 |
dc.relation | https://doi.org/10.1016/j.euroneuro.2019.02.003 |
dc.rights | cc-by-nc-nd (c) Elsevier B.V., 2019 |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/3.0/es |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Antipsicòtics |
dc.subject | Trastorn bipolar |
dc.subject | Esquizofrènia |
dc.subject | Antipsychotic drugs |
dc.subject | Manic-depressive illness |
dc.subject | Schizophrenia |
dc.title | Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/acceptedVersion |